Monte Rosa Therapeutics (GLUE) Enterprise Value (2020 - 2026)

Monte Rosa Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$678.1 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 763.48% year-over-year to -$678.1 million in Q1 2026; TTM through Mar 2026 was -$678.1 million, a 763.48% decrease from a year earlier, with the FY2025 full-year figure at -$129.9 million, up 65.91% from the prior year.
• Enterprise Value fell to -$678.1 million in Q1 2026 per GLUE's latest filing, from -$129.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$47.0 million in Q2 2023 and bottomed at -$678.1 million in Q1 2026.
• The 5-year median for Enterprise Value is -$113.4 million (2022), against an average of -$176.6 million.
• Across the five-year window, Enterprise Value soared 83.86% in 2022 and plunged 763.48% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$55.9 million in 2022, then slumped by 129.28% to -$128.1 million in 2023, then sank by 197.39% to -$381.0 million in 2024, then jumped by 65.91% to -$129.9 million in 2025, then slumped by 422.08% to -$678.1 million in 2026.
• Per Business Quant, the three latest GLUE Enterprise Value figures stand at -$678.1 million (Q1 2026), -$129.9 million (Q4 2025), and -$401.6 million (Q3 2025).